Inflarx vs Lyell Immunopharma
Inflarx and Lyell Immunopharma are similar in size: $33,162 and $36,000 of revenue in their latest fiscal years. Lyell Immunopharma grew faster (-41.0% against -81.5%). Inflarx kept more of each dollar of sales as profit: a net margin of -155582.1% against -762355.6%. Inflarx carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | InflarxIFRX, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $33,162 | $36,000 |
| Revenue growth | -81.5% | -41.0% |
| Net income | −$51.6m | −$274m |
| Operating margin | — | -748344.4% |
| Net margin | -155582.1% | -762355.6% |
| Return on equity | — | -87.0% |
| Free cash flow | — | −$151m |
| Cash | $18.8m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 161 |
| Market value | $110m | $252m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 29 sales |